Reading the annual reports…
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
ALGN · Nasdaq · United States · Orthopedic, Prosthetic & Surgical Appliances & Supplies
In shortALIGN TECHNOLOGY INC is profitable.
Financial health
Solid
Built from five areas over the last five annual reports. Tap an area to see the figures behind it.
| Operating marginShare of each sale left after running the business, before interest and tax. | 13.5% | 62/100 |
|---|---|---|
| Net marginShare of each sale left as profit after every cost, interest and tax. | 10.2% | 61/100 |
| Return on equityProfit earned on the money shareholders put in. Above 15% is strong. | 10.4% | 52/100 |
| Return on invested capitalProfit earned on all the capital used (equity and debt). Above 10% usually means a real competitive edge. | – | n/a |
Weight in the score: 25%
| Current ratioShort-term assets divided by short-term debts. Below 1 can mean tight cash. | 1.36× | 47/100 |
|---|---|---|
| Debt / equityDebt compared with the shareholders' stake. Above 2 is heavily indebted. | – | n/a |
| Net debt / EBITDAYears of operating profit needed to repay net debt. Below 2 is comfortable. | – | n/a |
| Interest coverageHow many times operating profit covers interest. Below 2 is risky. | – | n/a |
| Altman Z''Bankruptcy-risk model. Above 2.6 safe, below 1.1 distress. | 4.56 | 89/100 |
Weight in the score: 25%
| Free cash flow marginCash left from each sale after investments. The money that can pay dividends or reduce debt. | 12.2% | 69/100 |
|---|---|---|
| Free cash flow / net incomeHow much accounting profit turns into real cash. Near 1 or above is healthy. | 1.20× | 100/100 |
| Years with positive free cash flow (last 5) | 5 of 5 | 100/100 |
Weight in the score: 20%
| Profitable years (last 5) | 5 of 5 | 100/100 |
|---|---|---|
| Years of revenue decline (last 5) | 1 of 5 | 67/100 |
| Revenue growth volatility | 26.8% | 12/100 |
| Operating margin volatility | 4.3% | 70/100 |
Weight in the score: 20%
| Revenue growth, 3-year average | 2.6% | 31/100 |
|---|---|---|
| EPS growth, 3-year average | 7.0% | 60/100 |
Weight in the score: 10%
Fiscal year 2025 · change vs prior year
Annual figures as reported. Hover a bar or point for the exact value.
5 older years available with the 10-year history. Essential plan, from €8.25/month →
The last 5 fiscal years from the company's annual reports.
USD millions; negative values in parentheses.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | 3,953 | 3,735 | 3,862 | 3,999 | 4,035 |
| Cost of revenue | 1,017 | 1,101 | 1,155 | 1,200 | 1,324 |
| Gross profit | 2,935 | 2,634 | 2,707 | 2,799 | 2,711 |
| Research & development | 250 | 305 | 347 | 364 | 370 |
| Selling, general & admin | 1,709 | 1,674 | 1,703 | 1,763 | 1,756 |
| Operating income | 976 | 643 | 643 | 608 | 546 |
| Pre-tax income | 1,012 | 599 | 641 | 609 | 585 |
| Income tax | 240 | 237 | 196 | 188 | 175 |
| Net income | 772 | 362 | 445 | 421 | 410 |
| Diluted EPS | $9.69 | $4.61 | $5.81 | $5.62 | $5.65 |
| Diluted shares (millions) | 80 | 78 | 77 | 75 | 73 |
5 older years available with the 10-year history. Essential plan, from €8.25/month →
4.56 Safe zone
Estimates bankruptcy risk from working capital, retained earnings, operating profit and equity. Above 2.6 is considered safe, below 1.1 signals distress.
7/9
Nine yes-or-no tests on profitability, debt, liquidity and efficiency versus the prior year. 7 to 9 is strong, 0 to 3 is weak.
All figures: SEC EDGAR. Ratios and scores are computed by Scorvest (see how it works). Information only, not investment advice. How it works
Latest annual report: Jun 30, 2026 · Data updated Aug 5, 2026